Stroke
Conditions
Keywords
Stroke, large hemispheric infarction, osmotic drugs
Brief summary
Stroke remains the second leading cause of death worldwide, with 2%-8% of these being large hemispheric infarction (LHI) with an occupying effect and the worst prognosis. Even with medical and surgical treatment, the mortality of LHI with cerebral edema is as high as 20% to 30%. Current guidelines recommend supportive supervision, osmotic drugs, and decompressive hemicraniectomy (DHC) for the treatment of LHI, but not all patients with LHI are suitable for DHC, and not all of them can afford the high cost of DHC. In the real-world, the use of osmotic drugs is more common than DHC. The guideline recommends using mannitol or hypertonic saline to reduce cerebral edema and tissue displacement in patients with cerebral edema. Mannitol is the most widely used and longest-standing osmotic drug, and since 1965, hypertonic saline has been used to treat intracranial hypertension. Most of the previous studies compare the efficacy of DHC over medical therapy or compare the efficacy of mannitol with hypertonic saline, but there is an absence of clinical data on whether osmotic drug therapy can improve the clinical prognosis of patients with large hemispheric infarction at 90 days or even longer. Therefore, the purpose of this study was to investigate the association between the osmotic drug and clinical outcomes in large hemispheric infarction, with the aim of informing clinical decisions.
Detailed description
Diagnostic criteria for large hemispheric infarction (LHI): CT within 6 hours of onset showing hypointense areas \> 1/3 of the middle cerebral artery territory, or hypointense areas \> 50% of the middle cerebral artery territory within 6 hours to 72h of onset. LHI is strongly associated with severe cerebral edema, which can occur to varying degrees cerebral edema within hours or days of LHI. In recent years, endovascular treatment has significantly improved the revascularization of patients with large vessel occlusive cerebral infarction and reduced the incidence of malignant progression and mortality in patients with acute LHI, but many patients still suffer from malignant brain edema (MBE), which leads to the worsening of the disease.
Interventions
DRUGOsmotic drugs
Patients had used osmotic drugs within 72 hours of admission.
Sponsors
The Second Hospital University of South China
The Affiliated Hospital of Inner Mongolia Medical University
Second Affiliated Hospital of Wenzhou Medical University
Second Affiliated Hospital of Guangxi Medical University
Fujian Medical University Union Hospital
Huizhou Municipal Central Hospital
Haikou People's Hospital
Kashgar 1st People's Hospital
Ganzhou City People's Hospital
Guangzhou Medical University
Dongguan People's Hospital
The First Affiliated Hospital of Hunan University of Traditional Chinese Medicine
Hainan Traditional Chinese Medicine Hospital
Hainan People's Hospital
Sinopharm North Hospital
Huadu District People's Hospital of Guangzhou
Guangdong Provincial Hospital of Traditional Chinese Medicine
Nanfang Hospital, Southern Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥ 18 years 2. Within 72 hours of onset of the stroke 3. Meets the diagnostic criteria for acute ischaemic stroke in the Chinese Guidelines for the Diagnosis and Treatment of Acute Ischemic Stroke 2018 4. Meeting the diagnostic criteria for massive cerebral infarction in the Guidelines for the Surgical Treatment of Massive Cerebral Infarction: CT within 6 hours of onset showing hypointense areas \> 1/3 of the middle cerebral artery territory, or \> 50% of the middle cerebral artery territory within 6 hours to 72 hours of onset; 5. The patient consented and signed an informed consent form.
Exclusion criteria
1. Women who are pregnant or breastfeeding; 2. in combination with other serious comorbidities resulting in a life expectancy of less than 3 months 3. Those who are allergic or intolerant to osmotic drugs; 4. Those who have participated in other interventional clinical studies (which affecting the observation of outcomes in this cohort); 5. Those with a previous history of stroke and significant residual neurological disability (mRS ≥ 2 points) 6. Those who, in the judgment of the investigator, are not suitable for participation in this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| 90-day mortality | 90 days after onset | Mortality within 90 days after onset in patients with large hemispheric infarction who were eligible for inclusion criteria |
| Incidence of acute renal impairment | one year after onset | Incidence of acute renal impairment after onset in patients with large hemispheric infarction who were eligible for inclusion criteria |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| one year mRS | 1 year after onset | Modified Rankin Scale score within 1 year after onset in patients with large hemispheric infarction who were eligible for inclusion criteria |
| Incidence of early neurological deterioration | 30 days after onset | Incidence of early neurological deterioration within 30 days after onset in patients with large hemispheric infarction who were eligible for inclusion criteria |
| Incidence of malignant cerebral edema | 1 year after onset | Incidence of malignant cerebral edema within 1 year after onset in patients with large hemispheric infarction who were eligible for inclusion criteria |
| Clinical correction rate of brain herniation before decompressive hemicraniectomy | Up to 3 days | Clinical correction rate of brain herniation before decompressive hemicraniectomy |
| 90-day mRS | 90 days after onset | Modified Rankin Scale score within 90 days after onset in patients with large hemispheric infarction who were eligible for inclusion criteria |
| The actual incidence of decompressive hemicraniectomy | up to 24 hours | The actual incidence of decompressive hemicraniectomy after onset |
| Incidence of Symptomatic intracranial hemorrhage | up to 24 hours | Incidence of Symptomatic intracranial hemorrhage within 1 year after onset in patients with large hemispheric infarction who were eligible for inclusion criteria |
| Incidence of drug-related adverse events | up to 24 hours | Incidence of adverse events due to drugs within 1 year after the onset of large hemispheric infarction in patients who met the inclusion criteria |
| Incidence of need for decompressive hemicraniectomy | up to 24 hours | Incidence of need for decompressive hemicraniectomy after onset |
| 90-day mRS score change | 90 days after onset | Modified Rankin Scale score change within 90 days after onset in patients with large hemispheric infarction who were eligible for inclusion criteria |
Countries
China
Contacts
Primary ContactSuyue Pan, MD PH.D.
Outcome results
None listed